Max Fayans – Chembio Diagnostics, Inc.

Chembio

Webinar, May 27th- Fighting the Syphilis & HIV Epidemics: Voices from the Field

Chembio

Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu

Chembio

Chembio Diagnostics Announces CE Mark for DPP SARS-CoV-2 Antigen and IgM/IgG Test Systems

Chembio

Chembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors

Chembio

Chembio Diagnostics Receives ANVISA Approval for DPP SARS-CoV-2 Antigen Test System in Brazil

Chembio

Chembio Diagnostics Submits EUA Application for DPP SARS-CoV-2 Antigen Test System

Chembio

Chembio Diagnostics Receives FDA Approval for DPP HIV-Syphilis System

Chembio

Chembio Submits EUA Application for New DPP SARS-CoV-2 IgM/IgG Test System

Chembio

Chembio Announces Plans to Seek EUA Approval from FDA for Revised DPP COVID-19 IgM/IgG System and New DPP COVID-19 Antigen System

Chembio

Chembio Diagnostics Announces US Distribution Agreement to Expand Reach of DPP COVID-19 Serological Test with Thermo Fisher Scientific’s Healthcare Channel

© 2021 Chembio Diagnostics, Inc.. Privacy Policy | Terms & Conditions